152,312 Shares in GoodRx Holdings, Inc. (NASDAQ:GDRX) Acquired by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC purchased a new position in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 152,312 shares of the company's stock, valued at approximately $708,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of GoodRx by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 8,373,039 shares of the company's stock worth $38,935,000 after acquiring an additional 460,753 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of GoodRx by 22.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company's stock worth $9,264,000 after acquiring an additional 369,553 shares during the period. Clearbridge Investments LLC bought a new stake in shares of GoodRx during the fourth quarter worth $5,863,000. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of GoodRx by 38.7% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,228,836 shares of the company's stock valued at $5,714,000 after acquiring an additional 342,781 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of GoodRx by 9.1% in the fourth quarter. Geode Capital Management LLC now owns 1,071,761 shares of the company's stock worth $4,986,000 after purchasing an additional 89,032 shares in the last quarter. Hedge funds and other institutional investors own 63.77% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Wells Fargo & Company cut their target price on GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th. The Goldman Sachs Group decreased their target price on GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Truist Financial cut their target price on GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a research note on Thursday, April 10th. Finally, UBS Group decreased their price objective on GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. Five investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $6.55.

GoodRx Stock Performance

Shares of NASDAQ GDRX traded down $0.10 during trading on Wednesday, reaching $3.88. 145,819 shares of the company traded hands, compared to its average volume of 1,380,632. The firm has a 50 day simple moving average of $4.42 and a 200-day simple moving average of $4.63. The stock has a market capitalization of $1.38 billion, a PE ratio of -129.17, a P/E/G ratio of 2.46 and a beta of 1.24. GoodRx Holdings, Inc. has a 52-week low of $3.68 and a 52-week high of $9.26. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70.

GoodRx (NASDAQ:GDRX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.09 earnings per share for the quarter, beating analysts' consensus estimates of $0.04 by $0.05. GoodRx had a negative net margin of 2.05% and a positive return on equity of 5.35%. The business had revenue of $202.97 million for the quarter, compared to analysts' expectations of $202.25 million. During the same quarter in the previous year, the business posted $0.08 earnings per share. The business's revenue was up 2.6% compared to the same quarter last year. Equities research analysts anticipate that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.